2020 to today · Health, Food & Regulators

COVID-19 Hospital Payment Bonuses, Remdesivir Approval, PREP Act Hospital Immunity, and Pre-2020 Pandemic Plans

Period covered: 2017 to 2026 · 37 sources

Summary

In 2020 Congress paid hospitals 20 percent more for every Medicare patient with a COVID-19 diagnosis and then added a bonus for new treatments, the Food and Drug Administration approved remdesivir seven days after the World Health Organization's own trial found it had little or no effect on death, the government told the public not to take ivermectin in words a federal appeals court later said it had no authority to use, and the March 2020 declaration that gave drugmakers immunity was read by a state supreme court in 2026 to shield a hospital from a patient's death. The plans written before the pandemic had said not to do most of what was done: the government's 2017 guidance said an exposed household in a severe pandemic should stay home for up to three days, and the WHO's 2019 guidance said quarantine of the exposed and contact tracing were not recommended in any circumstances. At a Senate roundtable on September 28, 2026, patients, relatives, nurses, and doctors described what they say was done to patients in hospitals; no hospital or health agency took part, and the senator's office has released no report on it.

The CARES Act, signed March 27, 2020, changed what Medicare pays a hospital for a COVID-19 patient. The Centers for Medicare and Medicaid Services described the provision in its own guidance: it would "increase the weighting factor of the assigned Diagnosis-Related Group (DRG) by 20 percent for an individual diagnosed with COVID-19." For admissions on or after September 1, 2020, the agency added a condition that "claims eligible for the 20 percent increase in the MS-DRG weighting factor will also be required to have a positive COVID-19 laboratory test documented in the patient's medical record." For discharges from November 2, 2020 the agency added a second payment, the New COVID-19 Treatments Add-on Payment, which it said was "designed to mitigate potential financial disincentives for hospitals to provide new COVID-19 treatments," paying up to 65 percent of the amount by which a case's costs exceeded the standard payment. It ran until September 30, 2023.

Remdesivir

One of those new treatments was remdesivir, sold by Gilead as Veklury. The Food and Drug Administration authorized it for emergency use on May 1, 2020, on early results from a National Institutes of Health trial. That trial's final report, published in October 2020, found patients who received the drug recovered in a median of 10 days against 15 for placebo; deaths by day 29 were 11.4 percent with the drug and 15.2 percent without, a difference the trial did not find statistically significant. On October 15, 2020 the World Health Organization announced the results of its Solidarity trial, the largest test of the drug, and said remdesivir and three other drugs "appeared to have little or no effect on 28-day mortality." Seven days later, on October 22, 2020, the FDA gave remdesivir full approval, "the first treatment for COVID-19 to receive FDA approval." In November 2020 the WHO's guideline panel issued a conditional recommendation against using it in hospitalized patients, finding "no important effect on mortality, need for mechanical ventilation, time to clinical improvement, and other patient-important outcomes." The panel added that it was "not proving that remdesivir is ineffective; rather, there is no evidence based on currently available data that it does improve patient-important outcomes." In 2022 the WHO reversed itself, with a conditional recommendation for the drug in patients with non-severe disease at the highest risk of hospitalization and then, in September, in patients with severe disease.

Gilead set the price at $3,120 for a course for patients with private insurance. Its own earnings releases record Veklury sales of $2.8 billion in 2020 and $5.6 billion in 2021.

Ivermectin

On August 21, 2021 the FDA posted on social media: "You are not a horse. You are not a cow. Seriously, y'all. Stop it." Eight days later Anthony Fauci said on CNN: "Don't do it; there's no evidence whatsoever that it works and it could potentially have toxicity." Three doctors sued the agency over the posts. On September 1, 2023 the Fifth Circuit Court of Appeals ruled for them, writing: "FDA is not a physician. It has authority to inform, announce, and apprise, but not to endorse, denounce, or advise." The agency, the court said, "has identified no authority allowing it to recommend consumers 'stop' taking medicine." In March 2024 the FDA settled the case by agreeing to retire the consumer page and delete the posts.

What the court decided was who may tell a patient what to take. It did not decide whether the drug worked, and the trials that did are part of the record. The TOGETHER trial, published in March 2022, found hospitalization or a long emergency-room stay in 14.7 percent of patients given ivermectin and 16.3 percent given placebo, and the National Institutes of Health's treatment guidelines describe its result as "no apparent difference." The ACTIV-6 trial, published in October 2022, concluded that ivermectin "did not significantly improve time to recovery," a median of 12 days against 13. In the British PRINCIPLE trial, people who took ivermectin reported recovering about two days sooner, 14 days against 16, a difference the investigators said fell short of their threshold for a meaningful benefit, and they wrote that ivermectin "should not be prescribed as a treatment for COVID-19 in such populations."

In 2021 a Buffalo lawyer, Ralph Lorigo, went to court on behalf of families of hospitalized patients to force hospitals to administer ivermectin, and won orders in several states. The Daily Beast reported in September 2021 that he had "about 40 open cases across the country" and that "it's difficult to define exactly how many cases he's won and lost, since some of his patients have died while legal battles played out." In the interview, Senator Johnson said Lorigo handled about 200 cases, won about 70 in which three patients died, and lost about 120 in which all the patients died. No court record, study, or published tally states those numbers, and they rest solely on the senator's account.

The liability

The March 2020 declaration that gave vaccine makers immunity, which is on the Pfizer page, is broader than vaccines. It defines a covered countermeasure as "any antiviral, any other drug, any biologic, any diagnostic, any other device, or any vaccine, used to treat, diagnose, cure, prevent, or mitigate COVID-19," and it makes covered persons "immune from suit and liability under federal and state law with respect to all claims for loss caused by, arising out of, relating to, or resulting from the administration to or use by an individual of a covered countermeasure." On March 4, 2026 the Supreme Court of Indiana applied that to a hospital system and its doctors. Elmer Waggoner caught COVID-19 in January 2022, was intubated and put on a ventilator, developed a bed sore while he lay there that turned into a fatal infection, and died on March 29, 2022. His estate sued the hospital system and the doctors, alleging they had failed to treat the sore. The court held that the ventilator was a covered countermeasure and that the claims arose from its use: "Because the Estate's claims arise from the Providers' provision of a covered countermeasure during the public-health emergency, the Providers are 'covered persons' and immune under the PREP Act from civil liability for both federal and state-law claims."

The plans

The government had written down, before 2020, what it would do in a pandemic. The Centers for Disease Control and Prevention's 2017 Community Mitigation Guidelines said that voluntary home quarantine of exposed household members "might be recommended during severe, very severe, or extreme influenza pandemics," and that when it was, "all members of the household should stay home for up to 3 days (the estimated incubation period for seasonal influenza)." The guidelines put face masks for sick people and "preemptive, coordinated school closures and dismissals" in the same category, measures for a severe pandemic. The World Health Organization published its own guidance on non-pharmaceutical measures on September 19, 2019. A 2025 review in Frontiers in Public Health summarizes its recommendations: isolation of the sick at home, hand washing, and masks for people with symptoms were recommended in all circumstances; masks for people without symptoms were conditionally recommended in severe epidemics or pandemics only, along with school and workplace measures and limits on mass gatherings; and "contact tracing and quarantine of exposed individuals" and "entry and exit screening for infection in travelers" were not recommended in any circumstances, with border closure not recommended outside "extraordinary circumstances during a severe pandemic." The senator's phrase for what followed was that "they took the plans and threw them out the window." The documents are the plans.

The information

On December 10, 2020 a group of news organizations and technology companies calling itself the Trusted News Initiative, organized by the BBC, announced it would focus on "combatting the spread of harmful vaccine disinformation," with partners including the Associated Press, Reuters, the Washington Post, the Financial Times, Facebook, Google and YouTube, Microsoft, and Twitter, under an arrangement in which "TNI partners will alert each other to disinformation which poses an immediate threat to life." On January 10, 2023 Children's Health Defense and other publishers sued the Washington Post, the BBC, the Associated Press, and Reuters under the antitrust laws in federal court in Amarillo, Texas, alleging a group boycott through the initiative. The case was moved to Louisiana, and on September 18, 2023 a judge there sent it to the District of Columbia. On July 11, 2025 the Justice Department filed a statement of interest in the case; its release described the suit as alleging that the four organizations "colluded with one another and with the large digital platforms to suppress competition from independent perspectives that rival mainstream media," and the head of the Antitrust Division, Abigail Slater, said: "When companies abuse their market power to block out and deplatform independent voices and protect legacy media, they harm competition and threaten the free flow of information on which consumers depend." No court has ruled on the merits.

The senator's hearings

Johnson has held these sessions since 2022: a panel called "COVID-19: A Second Opinion" on January 24, 2022, a roundtable on vaccine safety on December 7, 2022, and, as chairman of the Permanent Subcommittee on Investigations, a hearing on May 21, 2025 on how health officials handled reports of myocarditis after vaccination. His office announced on September 16, 2026 a roundtable called "COVID-19 Hospital Protocols: Real Stories from Real People," for September 28, 2026 at 1 p.m. in the Kennedy Caucus Room of the Russell Senate Office Building. The advisory says he "will be joined by patients, families, doctors, and nurses to discuss how hospitals failed to administer proper care and treatment to patients suffering from COVID-19 throughout the pandemic," and that they will "share firsthand accounts of mistreatment and other experiences they witnessed at hospitals across the country." The roundtable took place on September 28 as scheduled. The speaker list posted by Children's Health Defense, which carried the livestream, names 21 people: wives, husbands, and other relatives of patients, one patient, nurses, physicians including Pierre Kory, the Oklahoma state senator and physician Randy Grellner, and the attorney Ralph Lorigo. No hospital, medical association, or federal health agency took part. Asked by Spectrum News why no doctors or hospitals had been invited to defend their policies, Johnson said no one had been denied the chance to submit testimony, that hospitals, doctors, and nurses with a different view had not asked to testify, and that his office would post their testimony if they sent it. The American Hospital Association declined to comment to Spectrum News.

Johnson said his office had received 583 testimonies from 46 states. He said he respected doctors, nurses, and modern medicine, apologized to people who had lost someone to what he called cruel hospital policies, and said requests for cheap generic drugs had been refused in favor of remdesivir and ventilators. The accounts were theirs, as Spectrum News and The Center Square reported them. Gail Seiler of Plano, Texas said that when she was admitted unvaccinated in December 2021 an intensive care doctor told her she was going to die, that she was pressed to accept remdesivir and a ventilator and refused the other drugs she asked for, that she was kept from her priest unless she took remdesivir, and that she recovered after her family took her home. Darla Smith of Pennsylvania, who went to court in 2021 to make a hospital give her husband ivermectin, said he never came home. A former trauma surgeon, James Miller, and a nurse, Donna Lowery, said they were disciplined or fired for advocating ivermectin or other treatments. Relatives in recorded testimony described remdesivir given over their objections and a ventilator placed without consent. Lorigo said he had represented 212 families in 40 states and won 72 court orders requiring hospitals to give ivermectin, that three of those patients died, and that all 140 patients in the cases he lost or could not bring in time died. Those are his own counts of his own cases. They are not a study, and the randomized trials described above, which compared patients given ivermectin with patients given a placebo, found no benefit.

None of the reports describe documents released at the roundtable, and as of September 30, 2026 the senator's press page listed no transcript or report of it.

← 2020 to today

Primary Sources (37)

Documents, court filings, official reports, and broadcasts cited in this report.

The Economic Times (YouTube). The interview this page grew out of; the senator's account of the Lorigo cases (about 200 cases, about 70 won, about 120 lost) is given on the page as his account only.
PRINCIPLE trial, University of Oxford. Published in the Journal of Infection in 2024: reported recovery about two days sooner (14 days against 16), short of the trial's threshold for a meaningful benefit; ivermectin should not be prescribed as a treatment for COVID-19 in such populations.
2017
Centers for Disease Control and Prevention, MMWR Recommendations and Reports 66(RR-1). Voluntary home quarantine of exposed household members might be recommended during severe, very severe, or extreme influenza pandemics, in which case all members of the household should stay home for up to 3 days (the estimated incubation period for seasonal influenza); face masks for the sick and preemptive, coordinated school closures in the same category.
2019
World Health Organization. The WHO's guidance on non-pharmaceutical measures for influenza pandemics, with its summary table of what is recommended in all circumstances, conditionally, and not recommended in any circumstances.
2020
Federal Register (85 FR 15198). Signed March 10, 2020, effective February 4, 2020; immunity for manufacturers, distributors, program planners, and qualified persons from any claim of loss except willful misconduct; the Act precludes liability claims alleging negligence by a manufacturer in creating a vaccine.
2020
Centers for Medicare and Medicaid Services. Section 3710 of the CARES Act: increase the weighting factor of the assigned Diagnosis-Related Group (DRG) by 20 percent for an individual diagnosed with COVID-19; revised in August 2020 so that admissions on or after September 1, 2020 also required a positive COVID-19 laboratory test documented in the patient's medical record.
2020
Food and Drug Administration. The emergency use authorization for remdesivir for hospitalized patients with severe COVID-19.
2020
CNBC. $520 a vial for private insurers, $3,120 for a typical course; $390 a vial for government programs.
2020
World Health Organization. Remdesivir, hydroxychloroquine, lopinavir/ritonavir and interferon regimens appeared to have little or no effect on 28-day mortality or the in-hospital course of COVID-19 among hospitalized patients; more than 11,000 patients in 30 countries.
2020
National Institutes of Health (NIH Research Matters). The ACTT-1 trial: median recovery of 10 days with remdesivir against 15 with placebo; mortality by day 29 of 11.4 percent against 15.2 percent, a difference that was not statistically significant.
2020
Food and Drug Administration. Full approval of Veklury (remdesivir) for hospitalized patients aged 12 and older, seven days after the WHO's Solidarity results.
2020
Centers for Medicare and Medicaid Services. The add-on payment for inpatient cases using new COVID-19 treatments, designed to mitigate potential financial disincentives for hospitals to provide new COVID-19 treatments; the lesser of 65 percent of the outlier threshold or 65 percent of the amount by which the case's costs exceed the standard payment; discharges from November 2, 2020 through September 30, 2023.
2020
STAT. The WHO guideline panel's conditional recommendation against remdesivir: no important effect on mortality, need for mechanical ventilation, time to clinical improvement, and other patient-important outcomes; the panel said it was not proving that remdesivir is ineffective.
2020
European Broadcasting Union. Partners including the BBC, AP, Reuters, the Washington Post, the Financial Times, Facebook, Google/YouTube, Microsoft, and Twitter; TNI partners will alert each other to disinformation which poses an immediate threat to life.
2021
Gilead Sciences. Veklury sales of $2.8 billion in 2020.
2021
WSLS. The FDA's August 21, 2021 post: You are not a horse. You are not a cow. Seriously, y'all. Stop it.
2021
Boston.com. Fauci on CNN: Don't do it; there's no evidence whatsoever that it works and it could potentially have toxicity.
2021
The Daily Beast. About 40 open cases across the country; it's difficult to define exactly how many cases he's won and lost, since some of his patients have died while legal battles played out.
2022
Office of Senator Ron Johnson. The January 24, 2022 panel.
2022
Gilead Sciences. Veklury sales of $5.6 billion in 2021.
2022
CIDRAP, University of Minnesota. The TOGETHER trial in the New England Journal of Medicine: 14.7 percent of the ivermectin group and 16.3 percent of the placebo group were hospitalized or held for extended emergency observation; 679 patients in each arm.
2022
National Institutes of Health. The Panel recommends against the use of ivermectin for the treatment of COVID-19, except in clinical trials; on TOGETHER: no apparent difference between the ivermectin and placebo arms for the primary outcome.
2022
Gilead Sciences. The company's announcement of the WHO's 2022 conditional recommendation for remdesivir in patients with severe COVID-19.
2022
CIDRAP, University of Minnesota. The ACTIV-6 trial in JAMA: median recovery 12 days with ivermectin against 13 with placebo, 1,591 patients; treatment with ivermectin, compared with placebo, did not significantly improve time to recovery.
2022
Office of Senator Ron Johnson. The December 7, 2022 roundtable.
2023
The Defender (Children's Health Defense). The plaintiff's own account of the suit filed in the Northern District of Texas, Amarillo Division, against the BBC, the Associated Press, Reuters, and the Washington Post, alleging a group boycott.
2023
United States Court of Appeals for the Fifth Circuit. FDA is not a physician. It has authority to inform, announce, and apprise, but not to endorse, denounce, or advise; the agency has identified no authority allowing it to recommend consumers stop taking medicine; the doctors' suit reinstated.
2023
United States District Court for the Western District of Louisiana (CourtListener). Judge Terry A. Doughty grants the motion to transfer the case to the District of Columbia.
2024
Newsweek. The agency agreed to delete the posts and retire its consumer page on ivermectin and COVID-19.
2025
Senate Permanent Subcommittee on Investigations. The subcommittee hearing of May 21, 2025, chaired by Johnson.
2025
Department of Justice. The statement of interest in Children's Health Defense v. Washington Post in the District of Columbia; Assistant Attorney General Abigail Slater: when companies abuse their market power to block out and deplatform independent voices and protect legacy media, they harm competition.
2025
Frontiers in Public Health (von Agris, Bell, Tacheva, and Brown). Summarizes the 2019 guidance: contact tracing and quarantine of exposed individuals and entry and exit screening for infection in travelers not recommended in any circumstances; border closure not recommended outside extraordinary circumstances during a severe pandemic; masks for the asymptomatic conditionally recommended in severe epidemics or pandemics only.
2026
Supreme Court of Indiana (Justia). A ventilator is a covered countermeasure; because the Estate's claims arise from the Providers' provision of a covered countermeasure during the public-health emergency, the Providers are covered persons and immune under the PREP Act from civil liability for both federal and state-law claims; the patient developed a bed sore on the ventilator and died March 29, 2022.
2026
Office of Senator Ron Johnson. September 28, 2026, Kennedy Caucus Room; patients, families, doctors, and nurses will share firsthand accounts of mistreatment and other experiences they witnessed at hospitals across the country.
2026
Children's Health Defense (CHD.TV livestream page). The livestream of the roundtable and its list of 21 speakers: relatives of patients, one patient, nurses, physicians including Pierre Kory, Oklahoma state senator Randy Grellner, and attorney Ralph Lorigo. Children's Health Defense is an advocacy group and a party to a lawsuit described on the page.
2026
Spectrum News 1 Wisconsin (Charlotte Scott). The September 28 roundtable: Darla Smith and Gail Seiler's accounts; Johnson's apology to families and his criticism of remdesivir and ventilators; his answer that hospitals and doctors with a different view had not asked to testify and that his office would post their testimony; the American Hospital Association declined to comment.
2026
The Center Square (Morgan Sweeney), via WJFW. Johnson's count of 583 testimonies from 46 states; Gail Seiler's account of her December 2021 hospital stay; James Miller and Donna Lowery on being disciplined or fired; recorded testimony on remdesivir and ventilators; Ralph Lorigo's count of his ivermectin cases (212 families, 72 court orders, 3 deaths among them, 140 cases lost or not brought in time, all died).

Documented Records (1)

Chronological entries extracted from the primary sources above.

2020
March 2020 to March 2026
The CARES Act paid hospitals 20 percent more for every Medicare patient with a COVID-19 diagnosis, and from November 2020 Medicare added a bonus of up to 65 percent of the extra cost of using a new treatment. One of those treatments, remdesivir, was given full approval on October 22, 2020, seven days after the World Health Organization's Solidarity trial found it had little or no effect on death, and it sold $8.4 billion in two years. The FDA told the public to stop taking ivermectin in words a federal appeals court held it had no authority to use; the randomized trials found the drug did not help. The March 2020 immunity declaration, read by Indiana's supreme court in 2026, bars a suit over a patient who died of an untreated bed sore on a ventilator.
“Increase the weighting factor of the assigned Diagnosis-Related Group (DRG) by 20 percent for an individual diagnosed with COVID-19.”
Congress; the Centers for Medicare and Medicaid Services; the Food and Drug Administration; the Department of Health and Human Services. Violates: The expectation that the government pays for care and not for a diagnosis, that the agency that approves medicine weighs the evidence in front of it and speaks within its authority, and that a family can go to court when a patient dies.. Source: MLN Matters SE20015: New Waivers for Inpatient Prospective Payment System (IPPS) Hospitals, Long-Term Care Hospitals (LTCHs), and Inpatient Rehabilitation Facilities (IRFs) due to Provisions of the CARES Act, Centers for Medicare and Medicaid Services

Timeline Events (8)

Dated events from this investigation in the site timeline.

September 28, 2026
At a Senate roundtable, patients, relatives, nurses, and doctors describe how they say hospitals treated COVID-19 patients; no hospital or health agency takes part
Sen. Ron Johnson said his office had received 583 testimonies from 46 states and would post testimony from anyone with a different view.
September 16, 2026
Senator Johnson announces a roundtable on hospital COVID-19 protocols for September 28
Patients, families, doctors, and nurses, in the Kennedy Caucus Room.
March 4, 2026
Indiana's supreme court holds a hospital system immune under the PREP Act for a ventilated COVID-19 patient's death
The ventilator was a covered countermeasure; the estate's claim that a bed sore went untreated was barred.
September 1, 2023
The Fifth Circuit: FDA is not a physician
The court held the agency had no authority to tell consumers to stop taking a medicine; in 2024 the FDA settled and deleted the posts.
August 21, 2021
The FDA posts: You are not a horse. You are not a cow. Seriously, y'all. Stop it.
Three doctors sued over the posts; the randomized trials of ivermectin, published the next year, found no benefit.
December 10, 2020
The BBC, AP, Reuters, the Washington Post, Facebook, Google, Microsoft, Twitter, and other partners announce a joint effort against vaccine disinformation
The Trusted News Initiative: partners will alert each other to disinformation which poses an immediate threat to life.
October 22, 2020
The FDA approves remdesivir seven days after the WHO's Solidarity trial found it had little or no effect on death
The first drug approved for COVID-19; a month later the WHO's guideline panel recommended against it in hospitalized patients.
March 27, 2020
The CARES Act adds 20 percent to Medicare's payment for every inpatient with a COVID-19 diagnosis
From September 1, 2020 a positive test had to be on the chart; a second add-on payment for new treatments followed in November.
COVID-19 Hospital Payment Bonuses, Remdesivir Approval, PREP Act Hospital Immunity, and Pre-2020 Pandemic Plans | Spirit of '76